GLP-1 reduces adverse cardiac events before weight loss: 3 notes

Adult patients taking Wegovy saw a reduced risk of experiencing a major adverse cardiovascular event within the first three months of treatment, according to a secondary analysis of the drug’s clinical trial data, presented May 12 at the European Congress on Obesity. Here are three notes from the secondary analysis: The “Semaglutide and Cardiovascular Outcomes … Read more

Physical activity promotes gut adaptation, responses to nutrients, and sensitivity to gut peptides

Physical activity is essential for body weight maintenance after body weight-loss, partly by promoting the coupling between energy intake and expenditure. However, the underlying mechanisms remain largely unknown. Here we demonstrate that running induces small intestine growth independently of GLP-2. In addition, exercise increases L-cell density in the small intestine and glucose-stimulated GLP-1 secretion, and … Read more

Nature’s Ozempic: What and how you eat can increase levels of GLP-1 without drugs

Despite the popularity of semaglutide drugs like Ozempic and Wegovy for weight loss, surveys suggest that most people still prefer to lose weight without using medications. For those preferring a drug-free approach to weight loss, research shows that certain nutrients and dietary strategies can naturally mimic the effects of semaglutides.

GLP-1s may cut risk of obesity-related cancers: 3 study notes  

A new study has found GLP-1s may reduce the risk of developing obesity-related cancers by 41% compared to bariatric surgery — a benefit researchers believe could be tied to the drugs’ ability to reduce inflammation.  The findings, published May 11 in The Lancet’s eClinicalMedicine journal, are based on data from more than 6,000 adults. Researchers … Read more

The Drug Pricing Scramble – OpEd

For the same pharmaceutical products, US prices can be anywhere between two and ten times higher in US markets compared to prices across the border. Nor is importation allowed, even though this would drive prices toward equilibrium by facilitating market competition. This problem has persisted for decades. US taxpayers and health insurance subscribers subsidize pharmaceutical … Read more

Azapeptide-based GLP-1 receptor agonist improves glucose metabolism in a diet-induced obesity model

Peptidomimetics, synthetically modified peptides which have been engineered to eliminate certain undesirable features of native therapeutic peptides including short half-lives, immunogenicity, and delivery challenges, are a growing class of peptide-based therapeutics. Azapeptides (C to N substitution(s)), a type of peptidomimetic with several examples in clinical use, are known to exhibit increased resistance to endogenous proteases, … Read more

Lost it on Wegovy? You might gain it all back in a year

A recent study presented at the European Congress on Obesity reveals that individuals using weight loss drugs, including newer GLP-1 medications, tend to regain all lost weight within a year of discontinuing the medication. While these drugs effectively induce weight loss, maintaining a healthy lifestyle through diet and exercise remains crucial for long-term success.